IN THE CLAIMS:

Claims 1-35. (Canceled)

36. (Currently Amended) A compound having cytoprotective activity, the compound having the formula:



wherein: n is 1 or 2; R^1 is a non-fused polycyclic, hydrophobic substituent having a bridged or spiro structure; R^x is selected from the group consisting of hydrogen and substituted or unsubstituted alkyl; R^{13} is hydrogen or substituted or unsubstituted alkyl; and, R^z is hydrogen, hydroxy, substituted or unsubstituted alkyl, or oxo, with the proviso that when the compound has the following structure:



R^x is not hydrogen.

37. (Original) The compound of claim 36 wherein said compound has the formula:



or



wherein R^1 and R^x are as defined in claim 36.

38. (Original) The compound of claim 36 wherein R^1 is adamantyl and R^x is hydrogen or methyl.

39. (Original) The compound of claim 38 wherein the compound has the formula:



or the enantiomer thereof.

40. (Original) The compound of claim 38 wherein the compound has the formula:



or the enantiomer thereof.

41. (Original) The compound of claim 36 wherein said compound has the formula:



or



wherein R^1 and R^x are as defined in claim 36.

42. (Original) The compound of claim 41 wherein R^1 is adamantyl and R^x is hydrogen, methyl or methylpropyl.

43. (Original) The compound of claim 42 wherein the compound has the formula:



or the enantiomer thereof.

44. (Original) The compound of claim 42 wherein the compound has the formula:



or the enantiomer thereof.

45. (Currently Amended) The ~~process~~ compound of claim ~~42~~ 38 wherein the compound has the formula:



or the enantiomer thereof.

Claims 46-51. (Canceled)

52. (New) The compound of claim 36 wherein R^1 is a bridged structure.

53. (New) The compound of claim 52 wherein the bridged structure is bicyclic, tricyclic or tetracyclic.

54. (New) The compound of claim 53 wherein said structure is selected from the group consisting of: bicyclo [1.1.0]butanyl; bicyclo[2.2.1]heptanyl; bicyclo[3.2.1]octanyl; bicyclo[4.3.2]nonanyl; bicyclo[4.3.2]undecanyl; tricyclo[2.2.1.0^1]heptanyl; tricyclo[5.3.1.1^1]dodecanyl; tricyclo[3.3.1.13,7]decanyl; tricyclo[5.4.0.0^{2,9}]undecanyl; and, tricyclo[5.3.2.0^{4,9}] dodecanyl.

55. (New) The compound of claim 54 wherein said structure is selected from the group consisting of: tricyclo[2.2.1.0^1]heptanyl; tricyclo[5.3.1.1^1]dodecanyl; tricyclo[3.3.1.13,7]decanyl; tricyclo[5.4.0.0^{2,9}]undecanyl; and, tricyclo[5.3.2.0^{4,9}] dodecanyl.

56. (New) The compound of claim 55 wherein said structure is tricyclo[3.3.1.13,7]decanyl.

57. (New) The compound of claim 36 wherein R^1 is a spiro structure.

58. (New) A compound having cytoprotective activity, the compound having the formula:



wherein: R^x is substituted or unsubstituted alkyl; R^{13} is hydrogen or substituted or unsubstituted alkyl; and, R^z is hydrogen, hydroxy, substituted or unsubstituted alkyl, or oxo.

59. (New) The compound of claim 58 wherein R^z is oxo.

60. (New) The compound of claim 59 wherein said compound has the structure:



61. (New) The compound of claim 60 wherein R^x is substituted alkyl.

62. (New) The compound of claim 60 wherein R^x is unsubstituted alkyl.

63. (New) A compound having cytoprotective activity, the compound having the formula:



wherein: R^x is selected from the group consisting of hydrogen and substituted or unsubstituted alkyl; R^{13} is hydrogen or substituted or unsubstituted alkyl; and, R^z is hydrogen, hydroxy, or substituted or unsubstituted alkyl.

64. (New) The compound of claim 63 wherein R^z is hydroxy.

65. (New) The compound of claim 64 wherein said compound has the structure:



66. (New) The compound of claim 65 wherein R^x is substituted alkyl.

67. (New) The compound of claim 65 wherein R^x is unsubstituted alkyl.

68. (New) The compound of claim 65 wherein R^x is hydroxy.